Skip to main content
SpringerLink
Log in

RCC2 contributes to tumor invasion and chemoresistance to cisplatin in hepatocellular carcinoma

  • Research Article
  • Published:
Human Cell Aims and scope Submit manuscript

A Correction to this article was published on 10 February 2021

This article has been updated

Abstract

Tumor metastasis and chemoresistance are the main causes of treatment failure and high mortality in hepatocellular carcinoma (HCC). Therefore, it is critical to clarify the biological action and potential mechanisms in HCC cells to develop novel therapeutics. The regulator of chromosome condensation 2 (RCC2), a component of the chromosomal passenger complex, was shown to have important roles in tumor development and radio-chemotherapy resistance. However, its role in the aggressive phenotypes and cisplatin (DDP)-resistance of HCC is not known. Therefore, this study aimed to investigate the role of RCC2 in HCC pathogenesis. Interestingly, we found that RCC2 was upregulated in HCC patient specimens and HCC cell lines and was correlated with the pathological grade of HCC. To evaluate the function of RCC2 in HCC cell, lentivirus vector-based shRNAs were transfected into HCC cells. Silencing RCC2 inhibited the HCC cell proliferation, migration, invasion, and increased the apoptosis rate upon DDP treatment. Further analysis showed that RCC2-mediated downregulation of the expression of survival proteins occurred via the AKT and Bcl2 pathways. Our results suggest that RCC2 might act as an oncogenic protein promoting metastatic behaviors and cisplatin resistance in HCC cells, and thereby could be a potential prognostic biomarker and therapeutic target for HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

Change history

References

  1. Mizejewski GJ. Does alpha-fetoprotein contribute to the mortality and morbidity of human hepatocellular carcinoma? A commentary. J Hepatocell Carcinoma. 2016;3:37–40.

    Article  Google Scholar 

  2. Thompson H. Cancer of the liver, esophagus, and nasopharynx. J Clin Pathol. 1988;41:359–459.

    Article  Google Scholar 

  3. Chi HC, Chen SL, Cheng YH, et al. Chemotherapy resistance and metastasis-promoting effects of thyroid hormone in hepatocarcinoma cells are mediated by suppression of FoxO1 and Bim pathway. Cell Death Dis. 2016;7:e2324.

    Article  CAS  Google Scholar 

  4. Dennert G, Horneber M. Selenium for alleviating the side effects of chemotherapy, radiotherapy and surgery in cancer patients (review). Cochrane Database Syst Rev. 2006;19:CD005037.

    Google Scholar 

  5. Amichetti M. Editorial hot topic: the association of radiotherapy and chemotherapy (guest editor: Maurizio Amichetti). Curr Drug Ther. 2010;5:151–251.

    Article  Google Scholar 

  6. Sakamoto K, Nagano H. Surgical treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus. Hepatol Res. 2017;47:957–62.

    Article  CAS  Google Scholar 

  7. Yang JM, Wang RQ, Bu BG, Zhou ZC, Luo YH. Effect of HCV infection on expression of several cancer-associated gene products in HCC. World J Gastroenterol. 1999;5:25.

    Article  Google Scholar 

  8. Stacey SN, Gudbjartsson DF, Sulem P, et al. Common variants on 1p36 and 1q42 are associated with cutaneous basal cell carcinoma but not with melanoma or pigmentation traits. Nat Genet. 2008;40:1313–8.

    Article  CAS  Google Scholar 

  9. Renault L, Kuhlmann J, Henkel A, Wittinghofer A. Structural basis for guanine nucleotide exchange on ran by the regulator of chromosome condensation (RCC1). Cell. 2001;105:245–55.

    Article  CAS  Google Scholar 

  10. Papini D, Langemeyer L, Abad MA, et al. TD-60 links RalA GTPase function to the CPC in mitosis. Nat Commun. 2015;6:7678.

    Article  Google Scholar 

  11. Bruun J, Kolberg M, Ahlquist TC, et al. Regulator of chromosome condensation 2 identifies high-risk patients within both major phenotypes of colorectal cancer. Clin Cancer Res. 2015;21:3759–70.

    Article  CAS  Google Scholar 

  12. Pang B, Wu N, Guan R, et al. Overexpression of RCC2 enhances cell motility and promotes tumor metastasis in lung adenocarcinoma by inducing epithelial-mesenchymal transition. Clin Cancer Res. 2017;23:5598–610.

    Article  CAS  Google Scholar 

  13. Gong S, Chen Y, Meng F, et al. RCC2, a regulator of the RalA signaling pathway, is identified as a novel therapeutic target in cisplatin-resistant ovarian cancer. FASEB J. 2019;33:5350–65.

    Article  CAS  Google Scholar 

  14. Buranjiang G, Kuerban R, Abuduwanke A, Li X, Kuerban G. MicroRNA-331-3p inhibits proliferation and metastasis of ovarian cancer by targeting RCC2. Arch Med Sci. 2019;15:1520–9.

    Article  CAS  Google Scholar 

  15. Yu H, Zhang S, Ibrahim AN, Wang J, Deng Z, Wang M. RCC2 promotes proliferation and radio-resistance in glioblastoma via activating transcription of DNMT1. Biochem Biophys Res Commun. 2019;516:999–1006.

    Article  CAS  Google Scholar 

  16. Zhou XD. Recurrence and metastasis of hepatocellular carcinoma: progress and prospects. Hepatobiliary Pancreat Dis Int. 2002;1:35–41.

    PubMed  Google Scholar 

  17. Huang X, Zeng Y, Xing X, et al. Quantitative proteomics analysis of early recurrence/metastasis of huge hepatocellular carcinoma following radical resection. Proteome Sci. 2014;12:22.

    Article  Google Scholar 

  18. Boucher E, Corbinais S, Brissot P, Boudjema K, Raoul J-L. Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen). Cancer Chemother Pharmacol. 2002;50:305–8.

    Article  CAS  Google Scholar 

  19. Ul-Islam S, Ahmed MB, Shehzad A, Ul-Islam M, Lee YS. Failure of chemotherapy in hepatocellular carcinoma due to impaired and dysregulated primary liver drug metabolizing enzymes and drug transport proteins: what to do? Curr Drug Metab. 2018;19:819–29.

    Article  CAS  Google Scholar 

  20. Moore JD. The Ran-GTPase and cell-cycle control. BioEssays. 2000;23:77–85.

    Article  Google Scholar 

  21. Xiong DD, Feng ZB, Lai ZF, et al. High throughput circRNA sequencing analysis reveals novel insights into the mechanism of nitidine chloride against hepatocellular carcinoma. Cell Death Dis. 2019;10:658.

    Article  Google Scholar 

  22. Madhunapantula SV, Mosca PJ, Robertson GP. The Akt signaling pathway. Cancer Biol Ther. 2011;12:1032–49.

    Article  CAS  Google Scholar 

  23. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene. 2005;24:7455–64.

    Article  CAS  Google Scholar 

  24. Slomovitz BM, Coleman RL. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res. 2012;18:5856–64.

    Article  CAS  Google Scholar 

  25. Dai J, Huang Q. Sestrin 2 confers primary resistance to sorafenib by simultaneously activating AKT and AMPK in hepatocellular carcinoma. Cancer Med. 2018;7:5691–703.

    Article  CAS  Google Scholar 

  26. Shimura T. Acquired radioresistance of cancer and the AKT/GSK3β/cyclin D1 overexpression cycle. J Radiat Res. 2011;52:539.

    Article  CAS  Google Scholar 

  27. Shimura T. Targeting the AKT/cyclin D1 pathway to overcome intrinsic and acquired radioresistance of tumors for effective radiotherapy. Int J Radiat Biol Relat Stud Phys Chem Med. 2017;93:381–5.

    Article  CAS  Google Scholar 

  28. Wu SY, Lan SH, Wu SR, et al. Hepatocellular carcinoma-related cyclin D1 is selectively regulated by autophagy degradation system. Hepatology. 2018;68:141–54.

    Article  CAS  Google Scholar 

Download references

Funding

None applicable.

Author information

Authors and Affiliations

  1. Department of General Surgery, The First Hospital of Jilin University, Changchun, 130021, Jilin, China

    Qingmin Chen, Peiqiang Jiang, Baoxing Jia, Yahui Liu & Ze Zhang

  2. Department of Hepatobiliary-Pancreatic Surgery, China-Japan Union Hospital of Jilin University, 126 Xiantai Street, Changchun, 130000, Jilin, China

    Ze Zhang

Authors
  1. Qingmin Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peiqiang Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Baoxing Jia
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yahui Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ze Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Yahui Liu or Ze Zhang.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

With the approval of the Ethic Committee of the First Hospital of Jilin University (2014204A), we collected HCC cancer tissues as well as matched adjacent normal tissues.

Informed consent

Written informed consents were acquired from each participating patient. The usage of cell lines and experimental animals (nude mice) was approved by the Scientific Ethics Committee of Jilin University (SXXK-JLU-2018-013).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chen, Q., Jiang, P., Jia, B. et al. RCC2 contributes to tumor invasion and chemoresistance to cisplatin in hepatocellular carcinoma. Human Cell 33, 709–720 (2020). https://doi.org/10.1007/s13577-020-00353-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13577-020-00353-7

Keywords

Search

Navigation